Somnomed (SOM: $0.66) has delivered a second good quarter in succession, with sales up 20% to $28.5 million. It follows on from the September quarter when sales were up by 20.3% in constant currency to $25.3 million.
In the quarter just passed, cash receipts were $26.6 million, with positive cashflow from operations of $1.5 million, and $0.86 million after investing activities, including plant and equipment.
Over the last half, the net cashflow from operations was $2.6 mil- lion, or $1.26 million after investing activities. The company fin- ished December with $18.5 million in cash.
Somnomed is capitalized at $143 million. The stock is up over 200% since the company's capital raise in May last year when $22.6 million was raised at $0.21 per share.
Whilst it remains a very good company, we recommend taking some profits at this point.
Bioshares recommendation: Take Profits
Disclaimer:
Information contained in this newsletter is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates herein expressed represent the current judgement of the publisher and are subject to change. Blake Industry and Market Analysis Pty Ltd (BIMA) and any of their associates, officers or staff may have interests in securities referred to herein (Corporations Law s.849). Details contained herein have been prepared for general circulation and do not have regard to any person’s or company’s investment objectives, financial situation and particular needs. Accordingly, no recipients should rely on any recommendation (whether express or implied) contained in this document without consulting their investment adviser (Corporations Law s.851). The persons involved in or responsible for the preparation and publication of this report believe the information herein is accurate but no warranty of accuracy is given and persons seeking to rely on information provided herein should make their own independent enquiries. Details contained herein have been issued on the basis they are only for the particular person or company to whom they have been provided by Blake Industry and Market Analysis Pty Ltd. The Directors and/or associates declare interests in the following ASX Healthcare and Biotechnology sector securities: Analyst MP: 1AD, ACR, AVR, CGS, CUV, CYC, DXB, IMM, LBT, MX1, OPT, NEU, PAB, PXS,RNO,SOM. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than $100 are not disclosed.
